Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials

Phase 3positivePositive

AI Analysis

Summary

Hengrui Pharma and Kailera Therapeutics' oral GLP-1 pill demonstrated encouraging efficacy in Phase 3 China trials for obesity and diabetes, though safety concerns were noted with high side effect rates.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Encouraging efficacy in late-stage China trials for obesity and diabetes indications, but high side effect rates reported

Importance:6/10

Sentiment:

0.30

GLP-1oral_formulationlate_stage_trialChinaobesitydiabetessafety_concerns

Related Companies

$KLRA

Read the original article

Published by Endpoints News on July 7, 2026 3:25 PM

Read Original